Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


New Antiviral Drug Inhibits Epidemic SARS, MERS & More


 

A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators recently reported in Science Translational Medicine. The findings support further development of the drug candidate for treating and preventing current coronavirus infections and potential future epidemic outbreaks.

Coronaviruses are a genetically diverse family of viruses that infect birds and mammals, with most coronavirus strains limited to infecting only certain hosts. Human coronaviruses, for example, cause up to 30 percent of common colds.

In the last 15 years, however, coronaviruses have demonstrated their ability to jump into new species. Zoonotic (animal) coronaviruses have infected humans, causing severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), severe diseases with high mortality rates ranging from 10 percent for SARS to 40 percent for MERS. The MERS-coronavirus continues to cause new infections in the Middle East.

"There's a real concern that the MERS coronavirus could escape broadly when millions of people visit Saudi Arabia for the Hajj," Mark Denison, MD, the Craig-Weaver Professor of Pediatrics and professor of Pathology, Microbiology and Immunology at Vanderbilt University School of Medicine, said of the event happening at the beginning of September. But to date, there has been no effective antiviral drug for any known coronavirus, he noted.

Denison and his team at Vanderbilt have studied the basic biology of coronaviruses for more than 20 years. In an effort to find chemical tools that would allow them to probe viral replication, graduate student Brett Case screened a series of compounds selected and provided by Gilead Sciences. Case demonstrated that one of the compounds was highly active against coronaviruses in cultured cells. The finding was a surprise, Denison said, because compounds in the same class (nucleoside analogs) have normally failed to inhibit coronavirus replication. The compound, called GS-5734, is currently in clinical development for treatment of Ebola virus disease.

Denison's longtime collaborator Ralph Baric, PhD, at the University of North Carolina and his team demonstrated that GS-5734 inhibits SARS-coronavirus and MERS-coronavirus replication in multiple in vitro systems, including cultures of primary human airway epithelial cells, which are the cells infected by respiratory coronaviruses. The researchers also showed that GS-5734 was effective against a circulating human coronavirus, bat coronaviruses, and bat coronaviruses that are considered "pre-pandemic" because they can infect cultured human cells.

Using a mouse model of SARS, the investigators demonstrated that both prophylactic and early therapeutic administration of GS-5734 reduced viral load in the lungs and improved respiratory functions. "This compound shows broad activity against a variety of human and animal coronaviruses and represents an exciting potential therapeutic for a family of viruses prone to emergence from animal reservoirs," Denison said.

Denison and his team at Vanderbilt will continue to use the compound "as a probe to try to understand the biology of the virus, how and why this drug works, and to identify new targets for inhibiting coronaviruses," he said.

"This is an exciting example of how pursuing fundamental research to understand the mechanisms of virus replication and pathogenesis can lead to an important compound with therapeutic potential."

WEB:
The Denison Lab at Vanderbilt
Science Translational Medicine Article

 
Share:

Related Articles:


Recent Articles

Study Challenges Idea That Lower BMI Shields Smokers from Fat-associated Health Risk

A lower body mass index (BMI) does not protect smokers from fat-associated health risks, according to a Vanderbilt University Medical Center (VUMC) study published in PLOS Medicine.

Read More

Nearly One-Third of Tennessee Parents are Worried Their Child has an Undiagnosed Mental Health Condition, New Poll Finds

One-third of Tennessee parents with children ages 6-17 are worried their child has an undiagnosed mental health condition, a new poll from the Vanderbilt Center for Child Health Policy found.

Read More

COVID-19 - Where We Stand

As the city moves deeper into reopening, leaders address the need for ongoing precautions and realities of vaccine development.

Read More

AMA Issues New Privacy Principles

From a fitness tracker to healthy eating app, data is everywhere ... but it isn't all protected by HIPAA. The AMA has created a set of privacy principles that put patients in charge of their information.

Read More

Paycheck Protection Program Flexibility Act

Deadlines and information on PPP and provider relief fund.

Read More

"What's Up Doc?" Dealing with a Delayed Patient Volume Bounce

Read More

Financing the Deal

The Nashville Health Care Council's annual "Financing the Deal" panel discussion is always highly anticipated. This year's virtual event was as popular as ever with a focus on deal-making trends and strategies.

Read More

Lending a Hand

Mentorship, wisdom offered to start-ups through Nashville Entrepreneur Center.

Read More

Health Care Council Explores the Road to Economic Recovery

Read More

Nashville-Based Startups Launch New Charity Initiatives

Charity-tech brands GeekCause, Generous, Givful and Kindful have jointly announced a range of new initiatives to support the important work of nonprofits during the COVID-19 pandemic.

Read More

Email Print
 
 

 

 


Tags:
Antiviral Drug Candidate, Brett Case, Coronavirus, GS-5734, Mark Denison, MERS, Ralph Baric, SARS, Vanderbilt University Medical Center, VUMC
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: